Stock Track | Castle Biosciences Surges After Smashing Q3 Earnings Estimates

Stock Track

Nov 05, 2024

Castle Biosciences, Inc. (NASDAQ:CSTL) stock soared 5.53% in after-hours trading on November 4th after the company reported impressive third quarter 2024 financial results that handily beat Wall Street expectations.

For the quarter ended September 30, 2024, the company reported earnings per share (EPS) of $0.08, significantly higher than the consensus analyst estimate of -$0.03. Castle Biosciences' revenue came in at $85.8 million, up 39.53% year-over-year and surpassing the $79.842 million estimate by 7.46%.

The strong earnings beat and robust revenue growth underscored the continued strength of Castle Biosciences' business and its ability to drive profitability. Investors cheered the exceptional results, bidding the stock higher in extended trading as the company demonstrated its ability to exceed lofty expectations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1179911745"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179911745\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179911745?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 05:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179911745","market":"us","top_or_hot":-1,"title":"Stock Track | Castle Biosciences Surges After Smashing Q3 Earnings Estimates","media":"Stock Track","content":"<p>Castle Biosciences, Inc. (NASDAQ:CSTL) stock soared 5.53% in after-hours trading on November 4th after the company reported impressive third quarter 2024 financial results that handily beat Wall Street expectations.</p>\n\n<p>For the quarter ended September 30, 2024, the company reported earnings per share (EPS) of $0.08, significantly higher than the consensus analyst estimate of -$0.03. Castle Biosciences' revenue came in at $85.8 million, up 39.53% year-over-year and surpassing the $79.842 million estimate by 7.46%.</p>\n\n<p>The strong earnings beat and robust revenue growth underscored the continued strength of Castle Biosciences' business and its ability to drive profitability. Investors cheered the exceptional results, bidding the stock higher in extended trading as the company demonstrated its ability to exceed lofty expectations.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Castle Biosciences Surges After Smashing Q3 Earnings Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Castle Biosciences Surges After Smashing Q3 Earnings Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-05 05:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Castle Biosciences, Inc. (NASDAQ:CSTL) stock soared 5.53% in after-hours trading on November 4th after the company reported impressive third quarter 2024 financial results that handily beat Wall Street expectations.</p>\n\n<p>For the quarter ended September 30, 2024, the company reported earnings per share (EPS) of $0.08, significantly higher than the consensus analyst estimate of -$0.03. Castle Biosciences' revenue came in at $85.8 million, up 39.53% year-over-year and surpassing the $79.842 million estimate by 7.46%.</p>\n\n<p>The strong earnings beat and robust revenue growth underscored the continued strength of Castle Biosciences' business and its ability to drive profitability. Investors cheered the exceptional results, bidding the stock higher in extended trading as the company demonstrated its ability to exceed lofty expectations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSTL","symbol_name":"Castle Biosciences, Inc.","start_time":0,"source_url":"","article_id":"1179911745","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179911745","pubTimestamp":1730756542,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Castle Biosciences, Inc.  stock soared 5.53% in after-hours trading on November 4th after the company reported impressive third quarter 2024 financial results that handily beat Wall Street expectations.For the quarter ended September 30, 2024, the company reported earnings per share  of $0.08, significantly higher than the consensus analyst estimate of -$0.03. Castle Biosciences' revenue came in at $85.8 million, up 39.53% year-over-year and surpassing the $79.842 million estimate by 7.46%.The s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CSTL":"Castle Biosciences, Inc."},"translate_title":"Castle Biosciences第三季度盈利预期大幅上涨","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSTL":1},"content_text":"Castle Biosciences, Inc. (NASDAQ:CSTL) stock soared 5.53% in after-hours trading on November 4th after the company reported impressive third quarter 2024 financial results that handily beat Wall Street expectations.\nFor the quarter ended September 30, 2024, the company reported earnings per share (EPS) of $0.08, significantly higher than the consensus analyst estimate of -$0.03. Castle Biosciences' revenue came in at $85.8 million, up 39.53% year-over-year and surpassing the $79.842 million estimate by 7.46%.\nThe strong earnings beat and robust revenue growth underscored the continued strength of Castle Biosciences' business and its ability to drive profitability. Investors cheered the exceptional results, bidding the stock higher in extended trading as the company demonstrated its ability to exceed lofty expectations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}